LE LENZ LENZ Therapeutics, Inc. Loading... : Investor Sentiment and Bull/Bear Views

The author expects LENZ to report a strong Q3 because the new telehealth channel simplified the patient journey and July prescriptions rose over 45% versus June. Google Trends data showing sustained and more purchase-intent-oriented VIZZ searches supports accelerating commercialization, with Q3 sales of roughly 45,000-55,000 packs versus 27,000 in Q2 seen as achievable. The catalyst is the Q3 report; the main stated risk is the prior weak Q2 demand.

The author argues LENZ's cash is less important than VIZZ's weak real-world retention: only 9 of 61 patients were still using the drop after three months, or 14.8%, versus the company's 42% repurchase-rate framing. They also highlight heavy advertising spend, about 40% bothersome side-effect reports, and management/insider signals such as dropping 'cash to profitability' language and Fidelity reducing its stake, making the cash-burn path risky. The key catalyst is the upcoming Q3 report, especially pack volume and any credible retention curve. The stated counter-risk is that real-world safety data is clean, the CEO has sold a company before, and a strong Q3 print could quickly change the author's mind.

The author argues LENZ has a best-in-class treatment for presbyopia and is positioned as the next gold standard for 5-8 years. If the company captures just 0.5% of the total addressable market, the stock could rise 10x from today's price, with fair value estimated at $500-800 per share by 2036 after 3.5% annual dilution. Catalysts are earnings, as the company currently has no other drug in the pipeline.